TY - JOUR
T1 - Blockage of interleukin-1β with canakinumab in patients with Covid-19
AU - Landi, Lorenza
AU - Ravaglia, Claudia
AU - Russo, Emanuele
AU - Cataleta, Pierluigi
AU - Fusari, Maurizio
AU - Boschi, Andrea
AU - Giannarelli, Diana
AU - Facondini, Francesca
AU - Valentini, Ilaria
AU - Panzini, Ilaria
AU - Lazzari-Agli, Luigi
AU - Bassi, Paolo
AU - Marchionni, Elisa
AU - Romagnoli, Rossella
AU - De Giovanni, Raffaella
AU - Assirelli, Marina
AU - Baldazzi, Federica
AU - Pieraccini, Fabio
AU - Rametta, Giovanna
AU - Rossi, Lucia
AU - Santini, Luca
AU - Valenti, Ivana
AU - Cappuzzo, Federico
N1 - Funding Information:
Lorenza Landi, Federico Cappuzzo, Ilaria Panzini, and Luca Santini express their solidarity and gratitude to all the patients and their families and to the colleagues of the authors of the present study, all risking their lives in first-line management of patients. Medical writing support was funded by Novartis Farma SpA. The authors also thank Health Publishing & Services srl who provided medical writing support.
Publisher Copyright:
© 2020, The Author(s).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 mg sc). Median time from diagnosis of Covid-19 by viral swab to administration of canakinumab was 7.5 days (range 0–30, IQR 4–11). Median PaO2/FiO2 increased from 160 (range 53–409, IQR 122–210) at baseline to 237 (range 72–533, IQR 158–331) at day 7 after treatment with canakinumab (p < 0.0001). Improvement of oxygen support category was observed in 61.4% of cases. Median duration of hospitalization following administration of canakinumab was 6 days (range 0–30, IQR 4–11). At 7 days, 58% of patients had been discharged and 12 (13.6%) had died. Significant differences between baseline and 7 days were observed for absolute lymphocyte counts (mean 0.60 vs 1.11 × 109/L, respectively, p < 0.0001) and C-reactive protein (mean 31.5 vs 5.8 mg/L, respectively, p < 0.0001).Overall survival at 1 month was 79.5% (95% CI 68.7–90.3). Oxygen-support requirements improved and overall mortality was 13.6%. Confirmation of the efficacy of canakinumab for Covid-19 warrants further study in randomized controlled trials.
AB - There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 mg sc). Median time from diagnosis of Covid-19 by viral swab to administration of canakinumab was 7.5 days (range 0–30, IQR 4–11). Median PaO2/FiO2 increased from 160 (range 53–409, IQR 122–210) at baseline to 237 (range 72–533, IQR 158–331) at day 7 after treatment with canakinumab (p < 0.0001). Improvement of oxygen support category was observed in 61.4% of cases. Median duration of hospitalization following administration of canakinumab was 6 days (range 0–30, IQR 4–11). At 7 days, 58% of patients had been discharged and 12 (13.6%) had died. Significant differences between baseline and 7 days were observed for absolute lymphocyte counts (mean 0.60 vs 1.11 × 109/L, respectively, p < 0.0001) and C-reactive protein (mean 31.5 vs 5.8 mg/L, respectively, p < 0.0001).Overall survival at 1 month was 79.5% (95% CI 68.7–90.3). Oxygen-support requirements improved and overall mortality was 13.6%. Confirmation of the efficacy of canakinumab for Covid-19 warrants further study in randomized controlled trials.
UR - http://www.scopus.com/inward/record.url?scp=85097500236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097500236&partnerID=8YFLogxK
U2 - 10.1038/s41598-020-78492-y
DO - 10.1038/s41598-020-78492-y
M3 - Article
C2 - 33311551
AN - SCOPUS:85097500236
VL - 10
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 21775
ER -